First Trust Advisors
CRSP icon

First Trust Advisors’s CRISPR Therapeutics CRSP Stock Holding History

First Trust Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,325
Closed -$2.85M – 2636
2025
Q4 		$2.85M Buy
+54,325
New +$3.25M ﹤0.01% 1718
2023
Q4 		– Sell
-8,910
Closed -$404K – 2356
2023
Q3 		$404K Sell
8,910
-87,488
-91% -$4.52M ﹤0.01% 2190
2023
Q2 		$5.41M Buy
+96,398
New +$5.47M 0.01% 1196
2023
Q1 		– Sell
-6,238
Closed -$254K – 2379
2022
Q4 		$254K Sell
6,238
-55,307
-90% -$2.93M ﹤0.01% 2334
2022
Q3 		$4.02M Buy
61,545
+52,930
+614% +$3.84M 0.01% 1311
2022
Q2 		$524K Buy
8,615
+232
+3% +$13.6K ﹤0.01% 2187
2022
Q1 		$526K Buy
8,383
+1,556
+23% +$97.7K ﹤0.01% 2241
2021
Q4 		$517K Sell
6,827
-35,470
-84% -$3.1M ﹤0.01% 2283
2021
Q3 		$4.73M Buy
+42,297
New +$5.31M 0.01% 1351
2021
Q2 		– Sell
-30,979
Closed -$3.77M – 2493
2021
Q1 		$3.77M Sell
30,979
-34,023
-52% -$5.14M ﹤0.01% 1410
2020
Q4 		$9.95M Sell
65,002
-1,309
-2% -$155K 0.01% 830
2020
Q3 		$5.55M Sell
66,311
-3,098
-4% -$275K 0.01% 921
2020
Q2 		$5.1M Sell
69,409
-21,724
-24% -$1.27M 0.01% 977
2020
Q1 		$3.87M Buy
+91,133
New +$4.71M 0.01% 966
2019
Q4 		– Sell
-24,085
Closed -$987K – 2398
2019
Q3 		$987K Buy
+24,085
New +$1.15M ﹤0.01% 1875
2019
Q2 		– Sell
-24,892
Closed -$889K – 2437
2019
Q1 		$889K Sell
24,892
-8,977
-27% -$310K ﹤0.01% 1908
2018
Q4 		$968K Sell
33,869
-59,478
-64% -$2.07M ﹤0.01% 1843
2018
Q3 		$4.14M Buy
93,347
+8,295
+10% +$434K 0.01% 1248
2018
Q2 		$5M Buy
+85,052
New +$4.85M 0.01% 1098

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Trust Advisors's CRSP Position: Q1 2026 in Review

First Trust Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 54,325 shares — an estimated $2.85M sold.

First Trust Advisors first reported a position in CRSP in Q2 2018 and held it in 19 quarters. The position peaked at $9.95M in Q4 2020. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • First Trust Advisors reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • First Trust Advisors sold 54,325 CRISPR Therapeutics shares in Q1 2026, an estimated $2.85M.
  • First Trust Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 19 quarters.
  • First Trust Advisors's CRISPR Therapeutics position peaked at $9.95M in Q4 2020.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.